Kalaris Therapeutics (KLRS) Share-based Compensation (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Share-based Compensation of $580000.0 for Q1 2026, up 55.08% year-over-year from $374000.0 in Q1 2025, and up 42.16% quarter-over-quarter from $408000.0 in Q4 2025.
Kalaris Therapeutics (KLRS) Share-based Compensation (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $580000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 55.08% year-over-year to $580000.0; the TTM figure through Mar 2026 stood at $2.2 million (up 79.08% YoY), while the FY2025 annual figure was $6.2 million, up 113.79% from the prior year.
- Share-based Compensation for Q1 2026 stood at $580000.0, up from $408000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $11.0 million in Q2 2022, with the low at -$17.6 million in Q4 2022.
- The 5-year median for Share-based Compensation is $591000.0 (2025), against an average of $3.5 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation plunged 199.81% in 2022, then jumped 1106.45% in 2025.
- Kalaris Therapeutics' Share-based Compensation stood at -$17.6 million in 2022, then surged by 156.93% to $10.0 million in 2023, then tumbled by 97.2% to $280000.0 in 2024, then surged by 45.71% to $408000.0 in 2025, then soared by 42.16% to $580000.0 in 2026.
- Business Quant data shows KLRS's Share-based Compensation at $580000.0 in Q1 2026, $408000.0 in Q4 2025, and $638000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | - |
| 10 | Kalaris Therapeutics | 97.57 Mn | 97.57 Mn | - | 644,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 644,000.00 |
| Jun 30, 2026 | 644,000.00 |
| Mar 31, 2026 | 580,000.00 |
| Mar 31, 2026 | 580,000.00 |
| Dec 31, 2025 | 408,000.00 |
| Dec 31, 2025 | 408,000.00 |
| Sep 30, 2025 | 638,000.00 |
| Sep 30, 2025 | 638,000.00 |
| Jun 30, 2025 | 591,000.00 |
| Jun 30, 2025 | 591,000.00 |
| Mar 31, 2025 | 374,000.00 |
| Mar 31, 2025 | 374,000.00 |
| Dec 31, 2024 | 280,000.00 |
| Dec 31, 2024 | 280,000.00 |
| Sep 30, 2024 | 262,000.00 |
| Sep 30, 2024 | 262,000.00 |
| Jun 30, 2024 | 322,000.00 |
| Jun 30, 2024 | 322,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Mar 31, 2024 | 31,000.00 |